Strategic Acquisition PathoQuest was acquired by Charles River Laboratories in January 2026, signaling cross-sell potential to Charles River's global pharma CRO base. Leverage combined biosafety and CGT QC capabilities to propose integrated solutions for viral safety, raw-material characterization, and cell/gene therapy QC. Coordinate with Charles River's BD teams to map target accounts and plan joint pitches.

Capacity Expansion Past investments include a $10M facility to support regulatory-compliant pre-release biosafety testing and characterization, indicating scalable capacity for growing CGT and vaccine programs. With testing hubs in Paris and Wayne, there are upsell opportunities for multi-site testing, faster turnarounds, and broader global coverage.

NGS Biosafety Focus iDTECT offers GMP-compliant, animal-free biosafety QC with rapid release for biotherapies, covering viral safety and genetic characterization of raw materials, cells, gene therapies, mAbs, and vaccines. Target biopharma and CGT manufacturers seeking regulatory-grade NGS testing and accelerated timelines; position PathoQuest as a partner to speed regulatory submissions.

Educational Outreach Launch of the Next-Gen Biosafety Masterclass signals a proactive market-engagement strategy. Use the program to generate leads, demonstrate thought leadership in NGS biosafety testing, and offer sponsored sessions or training packages to convert attendees into customers.

Geography Partnerships Operations in Paris and Wayne PA plus strategic partnerships (e.g., with Oxford Nanopore) and ongoing collaboration potential position PathoQuest to win EU/US CGT, vaccine, and mAb programs. Target manufacturers seeking cutting-edge sequencing options and consider cross-border service expansion through the Charles River ecosystem.